This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication **Hypertension** Treatment of essential hypertension in adults. **Cardiovascular prevention** Reduction of cardiovascular morbidity in patients with: - manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or; - type-2 diabetes mellitus with documented target-organ damage.
Therapeutic Area (MeSH)
ATC Code
C09CA07
ATC Item
telmisartan
Pharmacotherapeutic Group
Angiotensin II antagonists, plain
Active Substance (Summary)
INN / Common Names
EMA Name
Micardis
Medicine Name
Micardis
Aliases
N/ANo risk management plan link.
